These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Immunosuppressive substance in the sera of head and neck cancer patients.
    Author: Yamanaka N, Harabuchi Y, Himi T, Kataura A.
    Journal: Cancer; 1988 Oct 01; 62(7):1293-8. PubMed ID: 3416271.
    Abstract:
    Serum levels of immunosuppressive substance (IS) and immunosuppressive acidic protein (IAP) were studied by single radial immunodiffusion in 108 patients with head and neck cancer. Mean values of serum IS and IAP in patients with head and neck cancers were as follows: laryngeal carcinoma, 955 +/- 447 micrograms/ml (IS), 604 +/- 324 micrograms/ml (IAP); maxillary carcinoma, 896 +/- 384 micrograms/ml (IS), 568 +/- 246 micrograms/ml (IAP); nasopharyngeal carcinoma, 871 +/- 313 micrograms/ml (IS), 673 +/- 395 micrograms/ml (IAP); hypopharyngeal carcinoma, 1034 +/- 495 micrograms/ml (IS), 669 +/- 335 micrograms/ml (IAP). Except for IAP in hypopharyngeal carcinoma, these values were significantly higher than those of controls (IS, P less than 0.01; IAP, P less than 0.05). The overall positive rates of IS and IAP in the patient group were 46% and 37%, respectively. In patients with laryngeal carcinoma the positive rates of serum IS and IAP were found to be elevated as the disease stage advanced. The IS showed a higher positive rate than IAP in the advanced disease stage. Serial studies revealed that all patients who had recurrent disease after the treatment exhibited marked elevation of serum IS levels; in addition, patients with recurrent cancer showed significantly higher IS levels (1507 +/- 464 micrograms/ml) compared to patients who had remained free of disease in the follow-up period (640 +/- 143 micrograms/ml) (P less than 0.001). These data strongly suggests that serum IS and IAP levels are useful parameters for monitoring the disease stage of head and neck cancer patients.
    [Abstract] [Full Text] [Related] [New Search]